Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase I for Burkitt Lymphoma. According to GlobalData, Phase I drugs for Burkitt Lymphoma have a 68% ...

Loncastuximab tesirine is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Post-Transplant Lymphoproliferative Disorder. According to GlobalData, Phase II drugs for ...

Full approval is contingent upon positive results from confirmatory trials. Loncastuximab tesirine is a CD19-directed antibody and alkylating agent currently FDA-approved to treat refractory or ...

A new health operator is preparing to open an emergency room at the former Affinity Medical Center in Massillon. The Massillon Community Health and Innovation Center is planning to offer medical ...

A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and loncastuximab, have been studied in combination with rituximab for ...

Enrollment in the LOTIS-5 trial of loncastuximab tesirine-lpyl with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma has been completed. The phase 3, confirmatory LOTIS-5 ...

Amazon has many employee-led groups, which allow Amazonians to come together across businesses and locations around the world. Some examples include Warriors at Amazon (which includes military ...